I don't see much revenue growth until next year although we should start to see little with each quarter from now on. Cash burn rate here is over $1mil a month and with the new facility and preparing for production for the 3M tests will probably see that increase. Still waiting for a cardiac partner and final FDA approval for NT-proBNP. The cardiac partner may buy a financial stake like 3M did, more cash will be needed. This company is slow and methodical, but eventully gets to where its going.

dimar